Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients

Authors:

Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators reduce agonist-induced platelet activation and function. CFTR modulators, such as ivacaftor, present a promising therapeutic strategy in thrombocytopathies, including severe COVID-19. https://bit.ly/3HJykdt
Funding Information
  • Berlin Institute of Health (n/a)
  • Bundesministerium für Forschung, Technologie und Raumfahrt (01KI20160A, 01ZX1304B, 01ZX1604B, 01ZX1906A, 16GW0141, 16GW0247)
  • Deutsche Forschungsgemeinschaft (KFO339, KU1218/11-1, KU1218/12-1, KU1218/9-1, SFB 1449 B02, SFB 1449 B1, SFB 1470 A4, SFB-TR84 A2 and C9, SFB-TR84 C06 and C09, TRR295)
  • Deutsche Stiftung für Herzforschung (F-09-19)
  • Deutsches Zentrum für Herz-Kreislaufforschung (n/a)

This publication has 15 references indexed in Scilit: